{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T04:15:33Z","timestamp":1774066533035,"version":"3.50.1"},"reference-count":31,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Serum PSA has been widely applied to monitor prostate cancer after treatment. Compared to a single static value, PSA dynamics may provide additional prognostic information. Although PSA velocity and doubling time have demonstrated prognostic value, their clinical utility is limited by the need for prolonged longitudinal PSA follow-up. This study aimed to evaluate the prognostic potential of early postoperative PSA dynamics following radical prostatectomy. Methods: A retrospective cohort study of 3474 patients who underwent radical prostatectomy with available pre- and postoperative serum PSA measurements was analyzed. A population-based approach was used to characterize early postoperative PSA dynamics and estimate the time required for PSA to decline to undetectable levels (&lt;0.1 ng\/mL). Accordingly, patients were classified into early remission (\u226460 days), delayed remission (&gt;60 days), or persistent PSA (failure to achieve undetectable PSA). Associations between postoperative PSA dynamics and clinical outcomes were evaluated. Results: Biochemical recurrence rates differed across the early remission, delayed remission, and persistent PSA groups (5.3%, 7.7%, and 24.0%). All-cause mortality similarly increased across these groups (1.1%, 1.9%, and 5.8%, respectively). Cox proportional hazards models confirmed the difference in recurrence-free and overall survival among PSA clearance groups. Conclusions: Early postoperative PSA dynamics after radical prostatectomy are strongly associated with recurrence and survival outcomes. Both PSA trajectory patterns and PSA clearance speed carry important prognostic information. Early postoperative PSA monitoring may support risk stratification and guide individualized postoperative surveillance.<\/jats:p>","DOI":"10.3390\/cancers18050850","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T11:05:44Z","timestamp":1772795144000},"page":"850","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Early Postoperative PSA Dynamics and Prognostic Implications After Radical Prostatectomy"],"prefix":"10.3390","volume":"18","author":[{"given":"Yukun","family":"Tan","sequence":"first","affiliation":[{"name":"Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1433-9860","authenticated-orcid":false,"given":"Qing H.","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merve","family":"Dede","sequence":"additional","affiliation":[{"name":"Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6031-0156","authenticated-orcid":false,"given":"Ingold","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kaiser Permanente, Santa Clara, CA 95051, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Enterprise Data Engineering & Analytics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4013-5279","authenticated-orcid":false,"given":"Ken","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5512-9272","authenticated-orcid":false,"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"ref_1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e2332900","DOI":"10.1001\/jamanetworkopen.2023.32900","article-title":"Biochemical Recurrence and Risk of Mortality Following Radiotherapy or Radical Prostatectomy","volume":"6","author":"Falagario","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/01.ju.0000134888.22332.bb","article-title":"Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results","volume":"172","author":"Roehl","year":"2004","journal-title":"J. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jama.294.4.433","article-title":"Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy","volume":"294","author":"Freedland","year":"2005","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000481438","article-title":"Management of Biochemical Recurrence after Primary Curative Treatment for Prostate Cancer: A Review","volume":"100","author":"Artibani","year":"2018","journal-title":"Urol. Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.6004\/jnccn.2010.0012","article-title":"NCCN clinical practice guidelines in oncology: Prostate cancer","volume":"8","author":"Mohler","year":"2010","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1172\/JCI112185","article-title":"A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein","volume":"76","author":"Lilja","year":"1985","journal-title":"J. Clin. Investig."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nrc2351","article-title":"Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring","volume":"8","author":"Lilja","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM199104253241702","article-title":"Measurement of prostate-specific antigen in serum as a screening test for prostate cancer","volume":"324","author":"Catalona","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/0090-4295(89)90131-3","article-title":"Elevated serum prostate-specific antigen due to acute bacterial prostatitis","volume":"33","author":"Dalton","year":"1989","journal-title":"Urology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.juro.2006.10.097","article-title":"Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes","volume":"177","author":"Cookson","year":"2007","journal-title":"J. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","article-title":"EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1590\/s1677-5538.ibju.2016.0656","article-title":"Biochemical recurrence after radical prostatectomy: What does it mean?","volume":"44","author":"Srougi","year":"2018","journal-title":"Int. Braz. J. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","article-title":"Natural history of progression after PSA elevation following radical prostatectomy","volume":"281","author":"Pound","year":"1999","journal-title":"JAMA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0025-6196(11)62406-3","article-title":"PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer","volume":"76","author":"Roberts","year":"2001","journal-title":"Mayo Clin. Proc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1002\/cncr.20637","article-title":"Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy","volume":"101","author":"Rogers","year":"2004","journal-title":"Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.juro.2006.03.086","article-title":"Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: Natural history and prognostic significance","volume":"176","author":"Sengupta","year":"2006","journal-title":"J. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/pros.24198","article-title":"Natural history of an immediately detectable PSA following radical prostatectomy in a contemporary cohort","volume":"81","author":"Lonergan","year":"2021","journal-title":"Prostate"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41391-022-00638-y","article-title":"The natural history of a delayed detectable PSA after radical prostatectomy","volume":"26","author":"Szymaniak","year":"2023","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.juro.2013.04.073","article-title":"Predictive factors of oncologic outcomes in patients who do not achieve undetectable prostate specific antigen after radical prostatectomy","volume":"190","author":"Ploussard","year":"2013","journal-title":"J. Urol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00005392-200101000-00030","article-title":"Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy","volume":"165","author":"Blute","year":"2001","journal-title":"J. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/S0022-5347(05)65761-8","article-title":"Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases","volume":"166","author":"Moul","year":"2001","journal-title":"J. Urol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.juro.2010.02.017","article-title":"Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality","volume":"183","author":"Wright","year":"2010","journal-title":"J. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2013.07.039","article-title":"Positive surgical margins after radical prostatectomy: A systematic review and contemporary update","volume":"65","author":"Yossepowitch","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1002\/cncr.21895","article-title":"Cancer-specific survival and predictors of prostate-specific antigen recurrence and survival in patients with seminal vesicle invasion after radical prostatectomy","volume":"106","author":"Secin","year":"2006","journal-title":"Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/cncr.23293","article-title":"A nomogram predicting long-term biochemical recurrence after radical prostatectomy","volume":"112","author":"Suardi","year":"2008","journal-title":"Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.1002\/cncr.26169","article-title":"The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy","volume":"117","author":"Cooperberg","year":"2011","journal-title":"Cancer"},{"key":"ref_30","first-page":"S42","article-title":"Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy","volume":"172","author":"Moul","year":"2004","journal-title":"J. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/ijc.22161","article-title":"PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section","volume":"120","author":"Khatami","year":"2007","journal-title":"Int. J. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/5\/850\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:37:52Z","timestamp":1773391072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/5\/850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["cancers18050850"],"URL":"https:\/\/doi.org\/10.3390\/cancers18050850","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]}}}